LILRB1 KD suppressed disease progression, which was reversed by treatment with the synthetic antioxidant, liproxstatin-1, and RSL3 was effective at reducing tumour burden in a LILRB1 KD, but not control, MM mouse models. This evidence concerns the gene LILRB1 and neoplasm.